Diclofenac hydroxyethylpyrrolidine

Phase 1Small molecule

Diclofenac hydroxyethylpyrrolidine is one of 41 small molecule programs targeting Pancreatitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PancreatitisActive, not recruiting

PancreatitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

70 competitors in Pancreatitis

#DrugCompanyPhaseTrials

Voltaren

Novartis

Approved

5 2

Cysteine Hydrochloride

Novartis

Approved

1 3

Toradol

JJavelin Pharmaceuticals

Approved

2 4

Avycaz

PPhiladelphia Eye Associates

Approved

1 5

Imuran

LLegacy Health System

Approved

1 6

Cymbalta

Alnylam Pharmaceuticals

Phase 3

1 7

Octreotide

Johnson & Johnson

Phase 3

1 8

Zofran

Novartis

Phase 3

1 9

Resveratrol

NNational Cancer Institute (NCI)

Approved

1 10

Thymosin Alpha 1

SSun Yat-sen University

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Patient Preference1 trial

Patient Preferences, Analgesic Delivery Method and Pain Reduction in Spine Patients

Withdrawn·WWestern Galilee Hospital-Nahariya·N/A·NCT01263652

Children1 trial

Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries

Completed·IIBSA Institut Biochimique SA·Phase 4·NCT02132247·104 enrolled

Pain Management1 trial

Efficacy of PENNSAID® for Pain Management in the Emergency Department

Withdrawn·UUniversity of Utah·N/A·NCT01350622

Pancreatitis1 trial

Diclofenac vs. Placebo in a Randomized Double Blind Controlled Trial in Post ERCP Pancreatitis

Completed·—·Phase 1·NCT01946984·182 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Diclofenac hydroxyethylpyrrolidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Diclofenac hydroxyethylpyrrolidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Diclofenac hydroxyethylpyrrolidine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Western Galilee Hospital-Nahariya company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: WWestern Galilee Hospital-Nahariya

Diclofenac hydroxyethylpyrrolidine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Patient Preference1 trial

Children1 trial

Pain Management1 trial

Pancreatitis1 trial

References

Drug Info

Quick Facts

Related News